Claudia Fromond
OSE Immunotherapeutics (France) · 14 works · 64 citations · h-index 3
Top works
- First-in-Human Study in Healthy Subjects with the Noncytotoxic Monoclonal Antibody OSE-127, a Strict Antagonist of IL-7Rα
- Safety, pharmacokinetics, efficacy, and preliminary biomarker data of first-in-class BI 765063, a selective SIRPα inhibitor: Results of monotherapy dose escalation in phase 1 study in patients with advanced solid tumors.
- 983P Phase I dose escalation study in patients (pts) with advanced solid tumours receiving first-in-class BI 765063, a selective signal-regulatory protein α (SIRPα) inhibitor, in combination with ezabenlimab (BI 754091), a programmed cell death protein 1 (PD-1) inhibitor
- Abstract A129: Generation of YAP-TEAD Protein-Protein Interaction (PPI) inhibitors for the treatment of cancer
- Abstract 2200: A rational approach for discovery of inhibitors of YAP-TEAD interaction
- 557 A rational approach for discovery of inhibitors of YAP-TEAD interaction
- Abstract 2129: Predictive response biomarkers from Phase I clinical trial of a SIRPalpha inhibitor BI765063, stand-alone and in combination with ezabenlimab, a PD1 inhibitor, in patients with advanced solid tumors
- Abstract 894: Discovery of YAP-TEAD protein-protein interaction (PPI) inhibitors for cancer therapy
- 366 Combined exploratory immunophenotyping and transcriptomic tumor analysis in patients treated with OSE2101 vaccine in HLA-A2+ advanced non-small cell lung cancer (NSCLC) from the ATALANTE-1 trial
- Abstract 1993: Biomarker analyses from the Phase I clinical trial of the first-in-class SIRPa immune checkpoint inhibitor BI765063 in patients with advanced solid tumors
- Abstract 105: A rational approach for the discovery of inhibitors of NSD2 for the treatment of cancer
- Abstract 99: Identification of G9a inhibitors by AlphaLisa™ technology and hit confirmation using MT-Glo™
- 594 Identification of novel EZH2 inhibitor scaffolds
- Abstract 4524: A rational approach for the discovery of inhibitors of NSD2 for the treatment of multiple myeloma